Bently P. Doonan, MD, clinical assistant professor, Division of Hematology & Oncology, Department of Medicine, College of Medicine, the University of Florida, discusses current strategies for and associated challenges with the treatment of patients with advanced melanoma following disease progression on immune checkpoint inhibitors (ICIs).
Health Professionals
Radioactive Iodine Therapy in Thyroid Cancer May Increase Melanoma Risk
Patients with primary thyroid cancer who received radioactive iodine therapy have elevated risks for melanoma and other nonkeratinocyte skin cancers, according to study findings published in JAMA Network Open.
FDA Grants Fast Track Designation to IMM-1-104 for Advanced Melanoma
The FDA granted a fast track designation to IMM-1-104 (Immuneering Corp.) to treat patients with unresectable or metastatic NRAS-mutant melanoma whose disease progressed or is intolerant to PD-1-/PD-L1-based immune checkpoint inhibitors.1 Currently, the treatment is undergoing evaluation in a phase 2a clinical trial (NCT05585320)2, which enrolled patients with advanced solid tumors, including melanoma.
Does Indoor Tanning Affect Melanoma Tumor Mutational Burden?
Indoor tanning exposure was not associated with tumor mutational burden (TMB) in patients with cutaneous melanoma, in a retrospective cohort study. Higher TMB was linked to older age, head and neck tumors, and a history of nonmelanoma skin cancer (NMSC).